Erratum: Real-world effectiveness ofpharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder (JAMA Psychiatry (2018) 75:4 (347-355) DOI: 10.1001/jamapsychiatry.2017.4711);Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a finnish nationwide cohort of patients with bipolar disorder

JAMA Psychiatry

Volumn 75, Issue 4, 2018, Pages 347-355

  Lähteenvuo, Markku ^a   Tanskanen, Antti ^a,b,c   Taipale, Heidi ^a,b   Hoti, Fabian ^d   Vattulainen, Pia ^d   Vieta, Eduard ^e   Tiihonen, Jari ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d EPID Research Oy   (Finland)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DIXYRAZINE; FLUPENTIXOL; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LEVOMEPROMAZINE; LITHIUM CARBONATE; LONG ACTING DRUG; MELPERONE; OLANZAPINE; OXCARBAZEPINE; PERICIAZINE; PERPHENAZINE; PROCHLORPERAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SULPIRIDE; TOPIRAMATE; VALPROIC ACID; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; FEMALE; FINLAND; FINN (CITIZEN); FOLLOW UP; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REGISTER; RISK FACTOR; SELECTION BIAS; COMBINATION DRUG THERAPY; DELAYED RELEASE FORMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; BIPOLAR DISORDER; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GABAPENTIN; HUMANS; INJECTIONS, INTRAMUSCULAR; LITHIUM CARBONATE; MALE; MIDDLE AGED; PATIENT READMISSION; PERPHENAZINE; PROSPECTIVE STUDIES; PSYCHOTROPIC DRUGS; QUETIAPINE FUMARATE; RISK; RISPERIDONE; TREATMENT OUTCOME;

EID: 85044997748     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2022.0241     Document Type: Erratum

References (35)

1. Saunders KE, Goodwin GM. The course ofbipolar disorder. Adv Psychiatr Treat. 2010; 16(5):318-328. doi:10.1192/apt.bp.107.004903
2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995):743-800.
3. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006; 163(2):217-224.
4. Calabrese JR, Sanchez R, Jin N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry. 2017; 78(3):324-331.
5. Vieta E, Montgomery S, Sulaiman AH, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol. 2012; 22(11):825-835.
6. Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014; 1(5):351-359.
7. Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014; 2:15.
8. Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs. 2012; 26 (5):403-420.
9. National Institute for Health and Care Excellence. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. GC38. London, England: National Institute for Health and Care Excellence; 2006.
10. Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2017; 20(2):180-195.
11. Benraad CE, Kamerman-Celie F, van Munster BC, Oude Voshaar RC, Spijker J, Olde Rikkert MG Geriatric characteristics in randomised controlled trials on antidepressant drugs for older adults: a systematic review. Int J Geriatr Psychiatry. 2016; 31 (9):990-1003.
12. Vieta E. Observational, pragmatic, and clinical trials in bipolar disorder. J Clin Psychiatry. 2008; 69 (9):e27.
13. Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DPJ Lithium vs valproate vs olanzapine vs quetiapineasmaintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry. 2016; 15(1):53-58.
14. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry. 2011; 199(1):57-63.
15. Simhandl C, König B, Amann BL. Aprospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry. 2014; 75(3):254-262.
16. Joas E, Karanti A, Song J, Goodwin GM, Lichtenstein P, Landén M. Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Br J Psychiatry. 2017; 210(3): 197-202.
17. Song J, Sjölander A, Joas E, et al. Suicidal behavior during lithium and valproate treatment: a within-individual 8-year prospective study of 50,000 patients with bipolar disorder. Am J Psychiatry. 2017; 174(8):795-802.
18. Tanskanen A, Taipale H, Koponen M, et al. Drug exposure in register-based research - an expert-opinion based evaluation of methods. PLoS One. 2017; 12(9):e0184070.
19. Tanskanen A, Taipale H, Koponen M, et al. From prescription drug purchases to drug use periods - a second generation method (PRE2DUP). BMC Med Inform Decis Mak. 2015; 15:21.
20. Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S. Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons. Clin Epidemiol. 2016; 8:363-371.
21. Tiihonen J, Tanskanen A, Hoti F, et al. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry. 2017; 4(7):547-553.
22. Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017; 74(7):686-693.
23. Vieta E, Manuel Goikolea J, Martínez-Arán A, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry. 2006; 67(3):473-477.
24. Hojer J, Malmlund HO, Berg A. Clinical features in 28 consecutive cases of laboratory confirmed massive poisoning with carbamazepine alone. J Toxicol Clin Toxicol. 1993; 31(3):449-458.
25. Spiller HA, Krenzelok EP, Cookson E. Carbamazepine overdose: a prospective study of serum levels and toxicity. J Toxicol Clin Toxicol. 1990; 28(4):445-458.
26. Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study. PLoS Med. 2016; 13(8):e1002058.
27. Harit D, Aggarwal A, Kalra S, Chhillar N. Effect of carbamazepine and valproate monotherapy on cardiovascular risks in epileptic children. Pediatr Neurol. 2015; 53(1):88-90.
28. Taipale H, Tolppanen AM, Koponen M, et al. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. CMA J. 2017; 189(14): E519-E529.
29. Dodds TJ Prescribed benzodiazepines and suicide risk: a review of the literature. Prim Care Companion CNS Disord. 2017; 19(2):16r02037.
30. Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc. 2016; 91(11):1632-1639.
31. Sund R. Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health. 2012; 40(6):505-515.
32. Sanchez-Moreno J, Bonnín C, González-Pinto A, et al; CIBERSAM Functional Remediation Group. Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? a 12-month follow-up study. Eur Neuropsychopharmacol. 2017; 27(4):350-359.
33. Bonnín C del M, González-Pinto A, Solé B, et al; CIBERSAM Functional Remediation Group. Verbal memory as amediator inthe relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder. J Affect Disord. 2014; 160:50-54.
34. Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol. 2012; 22(5):339-346.
35. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016; 387(10027):1561-1572.